Clinical Trials
4
Active:0
Completed:0
Trial Phases
1 Phases
Phase 1:4
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (4 trials with phase data)• Click on a phase to view related trials
Phase 1
4 (100.0%)A Phase I, Open-label, Multicenter, Dose-Escalating Study to Evaluate the Safety and Tolerability of KH658 Gene Therapy in Participants with Neovascular Age-related Macular Degeneration
- First Posted Date
- 2025-02-13
- Last Posted Date
- 2025-02-13
- Lead Sponsor
- Chengdu Origen Biotechnology Co., Ltd.
- Target Recruit Count
- 9
- Registration Number
- NCT06825858
Safety and Tolerability of KH658 Gene Therapy in Subjects With Neovascular Age-related Macular Degeneration (nAMD)
- First Posted Date
- 2024-06-13
- Last Posted Date
- 2024-11-28
- Lead Sponsor
- Chengdu Origen Biotechnology Co., Ltd.
- Target Recruit Count
- 44
- Registration Number
- NCT06458595
- Locations
- 🇨🇳
Tianjin Medical University General Hospital, Tianjin, China
Safety and Tolerability of KH631 Gene Therapy in Subjects With Neovascular Age-related Macular Degeneration (nAMD)
- First Posted Date
- 2023-01-05
- Last Posted Date
- 2024-11-27
- Lead Sponsor
- Chengdu Origen Biotechnology Co., Ltd.
- Target Recruit Count
- 42
- Registration Number
- NCT05672121
- Locations
- 🇨🇳
Beijing Tongren Hospital, Capital Medical University, Beijing, China
Safety and Tolerability of KH631 Gene Therapy in Participants With Neovascular Age-related Macular Degeneration
- First Posted Date
- 2022-12-20
- Last Posted Date
- 2024-02-26
- Lead Sponsor
- Chengdu Origen Biotechnology Co., Ltd.
- Target Recruit Count
- 25
- Registration Number
- NCT05657301
- Locations
- 🇺🇸
Kanghong Investigative Site, Dallas, Texas, United States
News
First Patient Dosed in Phase 1 Trial of KH658 Gene Therapy for Wet AMD
Chengdu Origen and Vanotech have dosed the first patient in their VAN-2401 Phase 1 trial evaluating KH658, a gene therapy administered via a single suprachoroidal injection for wet AMD.